Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
-0.02 (-0.49%)
Real-time:   1:38PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.00 - 4.18
52 week 1.76 - 4.67
Open 4.05
Vol / Avg. 894,860.00/2.62M
Mkt cap 637.09M
P/E     -
Div/yield     -
EPS -0.23
Shares 158.09M
Beta 2.15
Inst. own 44%
May 20, 2015
Geron Corp Annual Shareholders Meeting (Estimated)
May 18, 2015
Geron Corp Annual Shareholders Meeting - Webcast
May 13, 2015
Geron Corp at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1734.64% -3093.67%
Operating margin -1760.89% -3149.35%
EBITD margin - -3145.27%
Return on average assets -22.09% -29.74%
Return on average equity -29.20% -37.45%
Employees 42 -
CDP Score - -


United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Officers and directors

Hoyoung Huh Ph.D Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 46
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 65
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Development and Technical Operations
Age: 50
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Business Development and Portfolio and Alliance Management
Age: 51
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Daniel M. Bradbury Independent Director
Age: 53
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 65
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters